Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Ascentage Pharma Group International - American Depository Shares
(NQ:
AAPG
)
19.11
-2.93 (-13.29%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Mar 20, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Ascentage Pharma Group International - American Depository Shares
Ascentage Pharma to Present Data From Four Preclinical Studies In Its Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2026
March 17, 2026
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Ascentage Pharma to Report Full Year 2025 Unaudited Financial Results and Provide Business Updates on March 25, 2026
March 11, 2026
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Ascentage Pharma to Participate in Three Upcoming Investor Conferences
February 23, 2026
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Ascentage Pharma Announces IND Clearance by the U.S. Food and Drug Administration for BTK Degrader APG-3288
January 06, 2026
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
This Hasbro Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
↗
November 10, 2025
Via
Benzinga
This Docebo Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations For Wednesday
↗
November 05, 2025
Via
Benzinga
Keurig Dr Pepper, Valneva, Venu Holding And Other Big Stocks Moving Lower On Monday
↗
August 25, 2025
Via
Benzinga
Earnings Scheduled For August 20, 2025
↗
August 20, 2025
Via
Benzinga
US Stocks Likely To Open Mixed As Trump Issues Tariff Letters: Experts Peg AI Investments As 'Durable Drivers Of Returns'
↗
July 08, 2025
U.S. stock futures were fluctuating on Tuesday after trimming gains on Monday. Futures of major benchmark indices were trading mixed.
Via
Benzinga
Topics
Artificial Intelligence
Government
Penguin Solutions, Merit Medical Systems And 3 Stocks To Watch Heading Into Tuesday
↗
July 08, 2025
Via
Benzinga
Ascentage Pharma Appoints Dr. Veet Misra as Chief Financial Officer and Eric Huang as Senior Vice President of Global Corporate Development and Finance
July 07, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Live from ASCO 2025 | Ascentage Pharma Releases Promising Clinical Data on Alrizomadlin Monotherapy and Combinations in Solid Tumors
June 02, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Live from ASCO 2025 | Ascentage Pharma Presents Clinical Data on Bcl-2 Inhibitor Lisaftoclax in Venetoclax-Refractory Patients in Oral Report
June 02, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
May 27, 2025
Via
Benzinga
Ascentage Pharma Announces Clinical Data of Lisaftoclax, Which Shows Therapeutic Potential in Venetoclax-Refractory Patients, Selected for Oral Report at ASCO 2025
May 22, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Ascentage Pharma Presents Results from Five Preclinical Studies at 2025 American Association of Cancer Research (AACR) Annual Meeting, Highlighting Strong Synergistic Effects of Olverembatinib Combined with Lisaftoclax
April 28, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Bitdeer Tech And Tempus AI Are Among Top 18 Mid-Cap Gainers Last Week (Apr 21-Apr 25): Are The Others In Your Portfolio?
↗
April 27, 2025
Top mid-cap stock performers last week: Ascentage Pharma, Ardagh Metal, Bitdeer Tech, Pegasystems, Impinj, Lufax, Tempus AI, Kymera Therapeutics.
Via
Benzinga
Topics
Artificial Intelligence
Ascentage Pharma To Present Data from Two Clinical Studies at 2025 ASCO Annual Meeting, Including Oral Presentation on Its Key Assets Lisaftoclax and Alrizomadlin
April 23, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Ascentage Pharma Announces Inclusion of Lisaftoclax and Olverembatinib in Chinese Society of Clinical Oncology (CSCO) 2025 Guidelines
April 21, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Argan Posts Upbeat Results, Joins KULR Technology, Abacus Global Management, W. R. Berkley And Other Big Stocks Moving Higher On Friday
↗
March 28, 2025
Via
Benzinga
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
↗
March 27, 2025
JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment.
Via
Benzinga
Ascentage Pharma Reports Full Year 2024 Unaudited Financial Results and Business Updates
March 27, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Earnings Scheduled For March 27, 2025
↗
March 27, 2025
Via
Benzinga
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
March 25, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
March 12, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
IPO Momentum Builds In 2025: Diginex, CTRL Group, And Others Post Strong Gains
↗
March 10, 2025
US IPO activity saw a meaningful recovery in 2024, with 38% more IPOs and 48% higher proceeds. 2025 may bring even more growth as 36 IPOs have already been priced this year, including Diginex's 600%...
Via
Benzinga
Topics
Initial Public Offering
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
March 05, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Ascentage Pharma Announces Partial Exercise of Underwriters’ Option to Purchase Additional American Depositary Shares
February 07, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
January 28, 2025
From
ASCENTAGE PHARMA GROUP INTERNATIONAL
Via
GlobeNewswire
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
